Recommendations for appropriately assessing patients with follicular lymphoma with disease progression after frontline treatment and options to consider as second-line therapy.
Videos
The panelists discuss the phase 3 INVICTUS trial of ripretinib and the phase 1 study of ripretinib intra-patient dose escalation.
Third-line treatment recommendations for patients with GIST and a discussion on side effect management.
Frontline treatment options available to treat newly diagnosed follicular lymphoma, based on a patient’s presentation, and recommendations for offering maintenance therapy following first-line treatment.
Important considerations when diagnosing follicular lymphoma, including the rationale for assessing patients’ FLIPI score and looking for any signs of histologic transformation.
Experts discuss the considerations of lines of therapy, comment on molecular testing, and the role of repeat biopsies.
The experts discuss a case presentation of a 66-year-old woman with heavily pretreated GIST, and comment on follow-up times and treatment options.
Prior to discussing treatment options for a 71-year-old woman with relapsed/refractory follicular lymphoma, John P. Leonard, MD, of Weill Cornell Medicine and NewYork-Presbyterian Hospital, sets the stage with an overview of the patient’s case.
Experts review 3 clinical cases, discuss treatment options and relevant clinical trials in GIST.
Hematology/oncology expert, John P. Leonard, MD, describes the rationale for treating an elderly patient with relapsed/refractory follicular lymphoma with a PI3K inhibitor in the third-line setting.
Luca Bertamini, MD, a hematologist oncologist at the Università delgi Studi di Torino, discusses outcomes and prognosis for patients with high-risk multiple myeloma.
Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Leora Horn, MD, discusses how real-world data of mobocertinib as treatment of refractory EGFR-positive non–small cell lung cancer and other real-world studies can impact the treatment paradigm.
Yi-Bin Chen, MD, comments on the need for improvements in patient assessment tools, measurements of response, and therapeutic agents for the management of acute GvHD in the future.
Yi-Bin Chen, MD, considers potential treatment options for steroid-refractory aGvHD and examines the results of the phase 3 REACH2 study of ruxolitinib.
Yi-Bin Chen, MD, discusses diagnostic criteria and measurements of response as they relate to the case of a 50-year-old woman with steroid-refractory acute GvHD.
Yi-Bin Chen, MD, defines acute graft-versus-host disease (aGvHD) as a complication of allogeneic transplant, discusses the clinical risk factors, and reviews prophylactic treatment options.
Yi-Bin Chen, MD, gives insight into the current accuracy of predictive prognostics and the potential use of biomarkers to risk stratify patients with acute GvHD in the future.
Yi-Bin Chen, MD, provides an overview of the case of a 50-year-old woman with steroid-refractory acute GvHD, including initial presentation, clinical work-up, and treatment.
Yi-Bin Chen, MD, reviews the case of a 50-year-old woman with steroid-refractory acute graft versus host disease (aGvHD) following allogeneic transplant and provides a discussion on treatment considerations for patients with aGvHD.
Othman Al-Sawaf, MD, discusses an analysis of minimal residual disease in patients with chronic lymphocytic leukemia given venetoclax and obinutuzumab on the CLL14.
Richard Finn, MD, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib in patients with unrespectable hepatocellular carcinoma.
Debu Tripathy, MD, discusses escalation and de-escalation of treatment in patients with HER2-positive breast cancer with HER2-targeted agents and chemotherapy.
Curtis Lachowiez, MD, discusses the interim analysis of the phase 1b/2 study of venetoclax in combination with standard intensive acute myeloid leukemia induction plus consolidation therapy with the FLAG-IDA regimen as treatment of patients with newly diagnosed or relapsed/refractory AML
Adam M. Brufsky, MD, PhD, discusses the use of neoadjuvant therapy for patients with triple–negative breast cancer.
Robert Coleman, MD, FACOG, FACS, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented on during the Association of Community Cancer Centers Annual Meeting.
Markus Moehler, MD, PhD, discusses the survival outcomes of nivolumab in combination with chemotherapy in patients with advanced gastric cancer.
Brian I. Rini, MD, discusses the dosing of nivolumab plus ipilimumab for patients with renal cell carcinoma.
Hossein Borghaei, DO, MS, discusses some adverse events (AEs) associated with the use of immunotherapy for lung cancer.
Sergio Giralt, MD, discusses the current unmet medical needs for patients with relapsed/refractory acute myeloid leukemia.